Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

1.750 -0.090 (-4.89%)
Streaming Delayed Price Updated: 3:57 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Recap: Aprea Therapeutics Q1 Earnings
Aprea Therapeutics (NASDAQ:APRE) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Aprea Therapeutics: Q2 Earnings Insights
  Aprea Therapeutics (NASDAQ:APRE) reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Aprea Therapeutics posted... 
Via Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Short Volatility Alert: Aprea Therapeutics, Inc.
On Tuesday, shares of Aprea Therapeutics, Inc. (NASDAQ: APRE) experienced volatile short activity. After the activity, the stock price went up +5.14% to $0.94. The overall sentiment for APRE has been... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board... 
Via Benzinga
Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target
Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here’s why this is significant for the biotech sector. 
Via InvestorPlace
Tesla, WD-40 Company And 40 Stocks Moving In Friday's Mid-Day Session
Gainers Aditxt, Inc. (NASDAQ: ADTX) shares surged 75.7% to $0.2812 after the company's Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Twitter And 20 Stocks Moving Premarket
Gainers Seritage Growth Properties (NYSE: SRG) rose 35.7% to $8.25 in pre-market trading after gaining around 10% on Thursday. Seritage Growth Properties filed its preliminary proxy materials with the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies
Aprea Therapeutics Inc (NASDAQ: APRE) can resume testing its eprenetapopt after a string of clinical holds on the therapy in August 2021.  The Company plans to study the drug in new trials across... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Stifel cut the price target on Adobe Inc. (NASDAQ: ADBE) from $700 to $600. Adobe shares rose 1.9% to $429.50 in pre-market trading. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results. 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. 
Via Benzinga
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or... 
Via Benzinga
Exposures Product Safety
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.